Leap Therapeutics Ownership
| LPTX Stock | USD 0.42 0.01 2.44% |
Leap |
Leap Stock Ownership Analysis
About 52.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.32. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Leap Therapeutics has Price/Earnings To Growth (PEG) ratio of 0.75. The entity recorded a loss per share of 1.64. The firm had not issued any dividends in recent years. Leap Therapeutics had 1:10 split on the 21st of June 2023. Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts. Leap Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 36 people. To find out more about Leap Therapeutics contact the company at 617 714 0360 or learn more at https://www.leaptx.com.Leap Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Leap Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Leap Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Leap Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Leap Therapeutics Outstanding Bonds
Leap Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Leap Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Leap bonds can be classified according to their maturity, which is the date when Leap Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| LEAR P 38 Corp BondUS521865AY17 | View | |
| US521865AZ81 Corp BondUS521865AZ81 | View | |
| US521865BB05 Corp BondUS521865BB05 | View | |
| LEA 26 15 JAN 32 Corp BondUS521865BC87 | View | |
| LEA 355 15 JAN 52 Corp BondUS521865BD60 | View | |
| US521865BA22 Corp BondUS521865BA22 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Leap Stock Analysis
When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.